Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Procept Biorobotics Corp (PRCT)

Procept Biorobotics Corp (PRCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,995,439
  • Shares Outstanding, K 55,879
  • Annual Sales, $ 224,500 K
  • Annual Income, $ -91,410 K
  • EBIT $ -93 M
  • EBITDA $ -87 M
  • 60-Month Beta 0.99
  • Price/Sales 8.71
  • Price/Cash Flow N/A
  • Price/Book 5.14

Options Overview Details

View History
  • Implied Volatility 59.23% (-11.49%)
  • Historical Volatility 65.90%
  • IV Percentile 40%
  • IV Rank 15.98%
  • IV High 121.81% on 02/21/25
  • IV Low 47.33% on 12/12/24
  • Expected Move (DTE 8) 2.35 (6.56%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 181
  • Volume Avg (30-Day) 595
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 13,776
  • Open Int (30-Day) 14,338
  • Expected Range 33.39 to 38.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 8
  • High Estimate -0.28
  • Low Estimate -0.35
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +8.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.80 +28.56%
on 11/21/25
38.11 -6.22%
on 12/05/25
+4.40 (+14.04%)
since 11/11/25
3-Month
27.80 +28.56%
on 11/21/25
40.10 -10.87%
on 09/17/25
-2.90 (-7.51%)
since 09/11/25
52-Week
27.80 +28.56%
on 11/21/25
92.92 -61.54%
on 12/16/24
-54.87 (-60.56%)
since 12/11/24

Most Recent Stories

More News
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025

SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative...

PRCT : 35.74 (+0.08%)
PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance

SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative...

PRCT : 35.74 (+0.08%)
PROCEPT BioRobotics (PRCT) Gets a Buy from Leerink Partners

Leerink Partners analyst Mike Kratky maintained a Buy rating on PROCEPT BioRobotics on October 14 and set a price target of $65.00. The company’s shares closed yesterday at $33.76.Elevate Your Investing...

PRCT : 35.74 (+0.08%)
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025

SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing...

PRCT : 35.74 (+0.08%)
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative...

PRCT : 35.74 (+0.08%)
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025 Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing...

PRCT : 35.74 (+0.08%)
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy

SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative...

PRCT : 35.74 (+0.08%)
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025

SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing...

PRCT : 35.74 (+0.08%)
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative...

PRCT : 35.74 (+0.08%)
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

PRCT : 35.74 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. It focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use...

See More

Key Turning Points

3rd Resistance Point 37.23
2nd Resistance Point 36.54
1st Resistance Point 36.13
Last Price 35.74
1st Support Level 35.02
2nd Support Level 34.33
3rd Support Level 33.91

See More

52-Week High 92.92
Fibonacci 61.8% 68.04
Fibonacci 50% 60.36
Fibonacci 38.2% 52.68
Last Price 35.74
52-Week Low 27.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar